Sales and ARR in line with ABGSCe Limited consensus estimate revisions are likely Strong margin due ...
Adj. EBITA 1% vs ABGSC, -7% vs cons Weaker demand in Denmark to drive 2% neg.
Redeye notes that Gasporox's report came in below Redeye Estimates (RRe) across the board while prod...
Redeye takes a more positive stance on Teneo AI following the Q3 report showing accelerating SaaS AR...
Redeye sees that the Q3 financials were not too far from our estimates (though we were slightly too ...
Redeye see a Q3 report from Stille confirming continued organic growth and expanding margins, albeit...
Redeye provides its initial take on ADDvise’s Q3 2024 report, which came in broadly below our estima...
Redeye sees another quarter in which BONESUPPORT delivers well on sales (beating our US CERAMENT G s...
Redeye comments on Evolution’s Q3-results which was close to our estimates and the company looks to ...
Net sales SEK 170m, -9% vs ABGSCe, -10% vs Factset cons.
Redeye’s first take on the Q3 report this morning. There were considerable changes in sales in the d...
Sales +4% vs. cons, adj. EBITA +20% vs. cons Minor positive consensus estimate revisions Awaiting im...
Redeye will likely increase its forecasts and Base Case following a solid Q3 report from Addnode.
Redeye retains its positive view of Carasent following a solid Q3 report showing accelerating organi...
Redeye continues to see a compelling long-term investment case.
Redeye sees high uncertainty until the underlying market recovers.
Limited estimate revisions Growth appears more capital-light than history suggests Trading at '25e E...
'24e-'26e sales up 3-2% In line to reach annual growth target of ~50% Revised FVR of SEK 30-45 (25-4...
Redeye provides a research update following the Q4 report recently published by Newbury.
Sales -8% vs. ABGSCe (-11% y-o-y), adj. EBIT -7% vs.
